GlassScriptPhysician profile
Alicja E Sundblade
NPI 1184059958
$2,355.06
in general payments reported to CMS, 2019-2025
32 companies · $618 in 2025
The $618 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $235 · 2023: $669 · 2024: $833 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $342.28 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $231.50 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $216.27 | 2022-2025 | |
| Pfizer INC. | $215.18 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.97 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $120.71 | 2022-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $113.95 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $99.54 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $86.92 | 2022-2024 | |
| Astellas Pharma US INC | $70.51 | 2023-2025 | Veozah |
| Abbott Laboratories | $67.71 | 2023-2024 | Octrode, Eterna |
| Shield Therapeutics INC | $59.76 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $46.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $41.89 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $41.24 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $40.47 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $38.69 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Medtronic, INC. | $36.31 | 2023-2024 | Venaseal, Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $35.05 | 2023-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $33.57 | 2022-2024 | Xarelto |
| Boston Scientific Corporation | $25.07 | 2023 | |
| Nevro Corp. | $23.91 | 2024 | Senza |
| Sanofi-Aventis U.S. LLC | $23.05 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.49 | 2024 | Evkeeza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.48 | 2025 | Xifaxan |
| Lundbeck LLC | $16.94 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.59 | 2025 | Caplyta |
| Corcept Therapeutics | $16.54 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $15.80 | 2023 | Contrave |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2023 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $14.39 | 2024 | Zoryve |
| Atland Pharmaceuticals, LLC | $13.99 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicja Sundblade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.